Robert van Lith

The blood and vascular cell compatibility of heparin-modified ePTFE vascular grafts

Prosthetic vascular grafts do not mimic the antithrombogenic properties of native blood vessels and therefore have higher rates of complications that involve thrombosis and restenosis. We developed an approach for grafting bioactive heparin, a potent anticoagulant glycosaminoglycan, to the lumen of ePTFE vascular grafts to improve their interactions with blood and vascular cells. Heparin was bound to aminated poly(1,8-octanediol-co-citrate) (POC) via its carboxyl functional groups onto POC-modified ePTFE grafts. The bioactivity and stability of the POC-immobilized heparin (POC-Heparin) were characterized via platelet adhesion and clotting assays. The effects of POC-Heparin on the adhesion, viability and phenotype of primary endothelial cells (EC), blood outgrowth endothelial cells (BOECs) obtained from endothelial progenitor cells (EPCs) isolated from human peripheral blood, and smooth muscle cells were also investigated. POC-Heparin grafts maintained bioactivity under physiologically relevant conditions in vitro for at least one month. Specifically, POC-Heparin-coated ePTFE grafts significantly reduced platelet adhesion and inhibited whole blood clotting kinetics. POC-Heparin supported EC and BOEC adhesion, viability, proliferation, NO production, and expression of endothelial cell-specific markers von Willebrand factor (vWF) and vascular endothelial-cadherin (VE-cadherin). Smooth muscle cells cultured on POC-Heparin showed increased expression of α-actin and decreased cell proliferation. This approach can be easily adapted to modify other blood contacting devices such as stents where antithrombogenicity and improved endothelialization are desirable properties.

A Thermoresponsive Biodegradable Polymer with Intrinsic Antioxidant Properties

Oxidative stress in tissue can contribute to chronic inflammation that impairs wound healing and the efficacy of cell-based therapies and medical devices. We describe the synthesis and characterization of a biodegradable, thermoresponsive gel with intrinsic antioxidant properties suitable for the delivery of therapeutics. Citric acid, poly(ethylene glycol) (PEG), and poly-N-isopropylacrylamide (PNIPAAm) were copolymerized by sequential polycondensation and radical polymerization to produce poly(polyethylene glycol citrate-co-N-isopropylacrylamide) (PPCN). PPCN was chemically characterized, and the thermoresponsive behavior, antioxidant properties, morphology, potential for protein and cell delivery, and tissue compatibility in vivo were evaluated. The PPCN gel has a lower critical solution temperature (LCST) of 26 °C and exhibits intrinsic antioxidant properties based on its ability to scavenge free radicals, chelate metal ions, and inhibit lipid peroxidation. PPCN displays a hierarchical architecture of micropores and nanofibers, and contrary to typical thermoresponsive polymers, such as PNIPAAm, PPCN gel maintains its volume upon formation. PPCN efficiently entrapped and slowly released the chemokine SDF-1α and supported the viability and proliferation of vascular cells. Subcutaneous injections in rats showed that PPCN gels are resorbed over time and new connective tissue formation takes place without signs of significant inflammation. Ultimately, this intrinsically antioxidant, biodegradable, thermoresponsive gel could potentially be used as an injectable biomaterial for applications where oxidative stress in tissue is a concern.

Biohybrid Strategies for Vascular Grafts

Despite the enormous advances realized in cardiology and cardiovascular surgery, approximately 500,000 deaths due to coronary heart disease occur annually in the US [166].

Process development for high-resolution 3D-printing of bioresorbable vascular stents

The recent development of “continuous projection microstereolithography” also known as CLIP technology has successfully alleviated the main obstacles surrounding 3D printing technologies: production speed and part quality. Following the same working principle, we further developed the μCLIP process to address the needs for high-resolution 3D printing of biomedical devices with micron-scale precision. Compared to standard stereolithography (SLA) process, μCLIP fabrication can reduce fabrication time from several hours to as little as a few minutes. μCLIP can also produce better surface finish and more uniform mechanical properties than conventional SLA, as each individual “fabrication layer” continuously polymerizes into the subsequent layer. In this study, we report the process development in manufacturing high-resolution bioresorbable stents using our own μCLIP system. The bioresorbable photopolymerizable biomaterial (B-ink) used in this study is methacrylated poly(1, 12 dodecamethylene citrate) (mPDC). Through optimization of our μCLIP process and concentration of B-ink components, we have created a customizable bioresorbable stent with similar mechanical properties exhibited by nitinol stents. Upon optimization, fabricating a 2 cm tall vascular stent that comprises 4000 layers was accomplished in 26.5 minutes.

Diazeniumdiolation of protamine sulfate reverses mitogenic effects on smooth muscle cells and fibroblasts.

After vascular interventions, endothelial cells are typically injured or lacking, resulting in decreased NO synthesis to maintain vascular health. Moreover, inflammation as a result of the tissue injury and/or the presence of an implanted foreign polymer such as a vascular graft causes excessive generation of reactive oxygen species (ROS) (e.g., superoxide), which can react with NO. The combination of the above creates a general decline in NO bioavailability, as well as oxidative stress due to less available NO to scavenge ROS. Localized NO delivery is an attractive solution to alleviate these issues; however, NO donors typically exhibit unpredictable NO payload release when using nitrosothiols or the risk of nitrosamine formation for synthetic diazeniumdiolates. The objective of this study was therefore to synthesize an NO donor from a biological peptide that could revert to its native form upon NO release. To this effect, protamine sulfate (PS), an FDA-approved peptide with reported vasodilator and anticoagulant properties, was diazeniumdiolated to form PS/NO. PS/NO showed diazeniumdiolate-characteristic UV peaks and NO release in physiological solutions and was capable of scavenging radicals to decrease oxidative stress. Furthermore, PS/NO selectively inhibits the proliferation of smooth muscle cells and adventitial fibroblasts, thereby reversing reported mitogenic properties of PS. Endothelial cell growth, on the other hand, was promoted by PS/NO. Finally, PS retained its anticoagulant properties upon diazeniumdiolation at clinically relevant concentrations. In conclusion, we have synthesized an NO prodrug from a biological peptide, PS/NO, that selectively inhibits proliferation of smooth muscle cells and fibroblasts, retains anticoagulant properties, and reverts back to its native PS form upon NO payload release.

Inhibiting intimal hyperplasia in prosthetic vascular grafts via immobilized all-trans retinoic acid

&NA; Peripheral arterial disease is a leading cause of morbidity and mortality. The most commonly utilized prosthetic material for peripheral bypass grafting is expanded polytetrafluoroethylene (ePTFE) yet it continues to exhibit poor performance from restenosis due to neointimal hyperplasia, especially in femoral distal bypass procedures. Recently, we demonstrated that periadventitial delivery of all‐trans retinoic acid (atRA) immobilized throughout porous poly(1,8 octamethylene citrate) (POC) membranes inhibited neointimal formation in a rat arterial injury model. Thus, the objective of this study was to investigate whether atRA immobilized throughout the lumen of ePTFE vascular grafts would inhibit intimal formation following arterial bypass grafting. Utilizing standard ePTFE, two types of atRA‐containing ePTFE vascular grafts were fabricated and evaluated: grafts whereby all‐trans retinoic acid was directly immobilized on ePTFE (atRA‐ePTFE) and grafts where all‐trans retinoic acid was immobilized onto ePTFE grafts coated with POC (atRA‐POC‐ePTFE). All grafts were characterized by SEM, HPLC, and FTIR and physical characteristics were evaluated in vitro. Modification of these grafts, did not significantly alter their physical characteristics or biocompatibility, and resulted in inhibition of intimal formation in a rat aortic bypass model, with atRA‐POC‐ePTFE inhibiting intimal formation at both the proximal and distal graft sections. In addition, treatment with atRA‐POC‐ePTFE resulted in increased graft endothelialization and decreased inflammation when compared to the other treatment groups. This work further confirms the biocompatibility and efficacy of locally delivered atRA to inhibit intimal formation in a bypass setting. Thus, atRA‐POC‐ePTFE grafts have the potential to improve patency rates in small diameter bypass grafts and warrant further investigation. Graphical abstract Figure. No caption available.

Antioxidant Polymers as Biomaterial

In this chapter, an overview will be given of progress in the development of antioxidant polymers and their therapeutic use. Oxidative stress has been identified as a key player in many disease conditions, as well as a result of commonly used implantable biomaterials. Systemic delivery of antioxidants is hampered by poor absorption, loss of bioactivity, limited time frame of effectiveness, and nontargeted lowering of oxidative stress. For this reason, polymers are being developed for localized, sustained antioxidant activity. Antioxidant entrapment in polymers will be discussed, as well as development of polymers with intrinsic antioxidant activity, with an emphasis on the latter.